PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II/III trial.

Bao, Zhaoshi; Li, Shouwei; Wang, Liang; Zhang, Bisi; Zhang, Peilong; Shi, Hepeng; Qiu, Xiaoguang; Jiang, Tao

Bao, Zhaoshi; Li, Shouwei; Wang, Liang; Zhang, Bisi; Zhang, Peilong; Shi, Hepeng; Qiu, Xiaoguang; Jiang, Tao.

Afiliación

Bao Z; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Li S; Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China.
Wang L; Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China.
Zhang B; Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Zhang P; Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, China.
Shi H; Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Qiu X; Beijing Pearl Biotechnology Limited Liability Company, Beijing, China.
Jiang T; Beijing Pearl Biotechnology Limited Liability Company, Beijing, China.

Chin Neurosurg J ; 9(1): 21, 2023 Jul 14.

Article en En | MEDLINE | ID: mdl-37443050

Palabras clave

Clinical trial; Glioblastoma; IDH mutation; PTPRZ1-MET; Phase II/III; Vebreltinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Chin Neurosurg J Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google